Cargando…
Alzheimer’s disease and blood-based biomarkers – potential contexts of use
Alzheimer’s disease (AD) is an irreversible, incurable, progressive neurodegenerative illness, where dementia symptoms gradually worsen over a number of years. The research of validated biomarkers for AD is essential to improve diagnosis and accelerate the development of new therapies. Biochemical m...
Autor principal: | Zvěřová, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055879/ https://www.ncbi.nlm.nih.gov/pubmed/30050302 http://dx.doi.org/10.2147/NDT.S172285 |
Ejemplares similares
-
Plasma cortisol in Alzheimer’s disease with or without depressive symptoms
por: Zvěřová, Martina, et al.
Publicado: (2013) -
Blood‐based biomarkers for Alzheimer's disease
por: Leuzy, Antoine, et al.
Publicado: (2021) -
Blood-based molecular biomarkers for Alzheimer’s disease
por: Zetterberg, Henrik, et al.
Publicado: (2019) -
Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation
por: Cummings, Jeffrey, et al.
Publicado: (2022) -
Advances in blood-based protein biomarkers for Alzheimer's disease
por: Clark, Lorraine Fuhrmann, et al.
Publicado: (2013)